Drugs / LUCAR-G39D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06395870 | May 2024 → Jun 2026 overdue | B-cell non-Hodgkin lymphoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-06 | Nanjing Legend Biotech Co. | Results Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 legendbiotech.com ↗
Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D demonstrate encouraging safety and efficacy in B-cell non-Hodgkin lymphoma |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-06 | Nanjing Legend Biotech Co. | Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 legendbiotech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUCAR-G39D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06395870 ↗ |
| Modality | Cell therapy | “a dual-targeted cell preparation” NCT06395870 ↗ |